GlassScriptPhysician profile
Andrew K Bean
NPI 1881649523
$5,699.23
in general payments reported to CMS, 2019-2025
32 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $388 · 2021: $516 · 2022: $756 · 2023: $1,172 · 2024: $1,152 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.65 |
| Education | $196.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,379.01 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $465.17 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $429.21 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $372.20 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $335.85 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $326.91 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $283.22 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $280.43 | 2020-2024 | Siliq, Jublia, Arazlo |
| Amgen INC. | $255.89 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $210.26 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $151.29 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $147.49 | 2019-2025 | Ilumya |
| Incyte Corporation | $142.86 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.05 | 2023-2025 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $111.49 | 2019-2025 | Nemluvio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $98.00 | 2021-2023 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $83.92 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $78.48 | 2022-2025 | Adbry |
| Genentech USA, INC. | $74.11 | 2019-2024 | Erivedge |
| Organon LLC | $69.69 | 2024-2025 | Hadlima, Vtama |
| Biofrontera INC. | $62.57 | 2020-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $50.79 | 2023 | Ycanth |
| Arcutis Biotherapeutics, INC. | $29.02 | 2023 | |
| Blueprint Medicines Corporation | $21.88 | 2024 | Ayvakit |
| Dusa Pharmaceuticals, INC. | $17.63 | 2019 | |
| Kerecis Limited | $17.18 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Krystal Biotech INC | $16.10 | 2025 | Vyjuvek |
| Dermira, INC. | $16.03 | 2019 | |
| Aclaris Therapeutics, INC. | $15.03 | 2019 | |
| Celgene Corporation | $13.38 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.85 | 2019 | |
| Allergan, INC. | $7.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.